Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04535531 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
A Phase 3 study, sponsored by Novan.
- Completed
- Registry status
- Phase 3
- Development phase
- 891
- Enrollment target
NCT04535531 is a Phase 3 study that has completed, run by Novan. The registered enrollment target is 891 participants.
The verdict
NCT04535531, a Phase 3 study, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 891 participants
- Enrollment target
Study Summary
This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 850 subjects 6 months of age and older with molluscum contagiosum (MC). Subjects or their caregivers will apply SB206 10.3% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.
Interventions
- DRUG vehicle gel
- DRUG SB206 10.3% berdazimer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 891 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2021-07-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04535531
The ClinicalTrials.gov registry entry for NCT04535531 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 891 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vehicle gel is the first listed.
NCT04535531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04535531 about?
NCT04535531 is a clinical study titled "A Phase 3 Molluscum Contagiosum Efficacy and Safety Study". This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 850 subjects 6 months of age and older with molluscum contagiosum (MC). Subjects or their caregivers will apply SB206 10.3% or Vehicle Gel once daily for a minimu...
What is the current status of trial NCT04535531?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 891 participants. The study started on 2020-09-01. Estimated completion is 2021-07-28.
What interventions are being tested in trial NCT04535531?
The interventions under investigation include: vehicle gel (DRUG), SB206 10.3% berdazimer (DRUG).
Who is sponsoring clinical trial NCT04535531?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.